Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 7,047 shares at $19.81 ($140K) on 2025-01-30, disclosed to the SEC on 2025-01-30.
Open-market sale of $140k NRIX by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.81 | 3,357 | $67K | 47.6% |
| 2 | $19.81 | 3,357 | $67K | 47.6% |
| 3 | $20.33 | 333 | $7K | 4.8% |
| Total | $19.83 avg | 7,047 | $140K | 100% |
| Filing → |
| NRIX | SELL | 2026-08-05 | $109K | — | Filing → |
| NRIX | SELL | 2026-07-30 | $90K | — | Filing → |
| NRIX | SELL | 2026-06-25 | $108K | — | Filing → |